🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-520149-22-00
Authorised Phase I/II

mRNA Therapy to restore lymphatic flow in secondary lymphedema

2024-520149-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire De Toulouse
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
18/05/2026
Enrollment target
9
Sites
France

Condition studied

Lymphedema

Eligibility

Age group
18-64 years, 65+ years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-520149-22-00 on CTIS ↗ ← All trials in the EU